Retatrutide

Triple Agonist · GIP / GLP-1 / Glucagon Receptor Agonist

Retatrutide is an investigational multi-receptor peptide targeting GIP, GLP-1, and glucagon pathways and is being studied for its potential to support metabolic health and weight management.

Trusted Quality

Retatrutide vial reference artwork — View one-page graphic ↗

Quick Facts

Triple agonist targeting GIP, GLP-1, and glucagon receptors
Investigational peptide for metabolic and obesity research
Supports appetite regulation and satiety
May improve glycemic control and insulin sensitivity
May enhance energy expenditure and fat utilization
Long half-life supports once-weekly administration

Research Highlights

Demonstrated substantial weight reduction in clinical research
Improved HbA1c, fasting glucose, and insulin sensitivity
Reduced appetite and caloric intake via incretin pathways
Increased energy expenditure and favorable fat-mass reduction
Multi-agonist mechanism may provide broader efficacy than single-pathway agents

How Retatrutide Works

GIP Agonism

Supports insulin response and adipose metabolism.

GLP-1 Agonism

Promotes satiety, slows gastric emptying, and supports healthy blood sugar regulation.

Glucagon Agonism

Increases energy expenditure and supports fat utilization.

Protocol Tips

Start low and titrate gradually
Stay hydrated and prioritize protein intake
Monitor appetite, GI tolerance, and energy
Pair with a structured nutrition and activity plan
Consistency is key for best results

Cycle Guidance

Typical cycle length: 12–20 weeks
Reassess goals and response before continuation
Breaks between cycles may be considered
Use as part of a broader metabolic support strategy

Ask about available vial sizes and current pricing.

Check availability →